These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 1957127)
1. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders. Schvarcz R; Glaumann H; Weiland O; Norkrans G; Wejstål R; Frydén A Scand J Infect Dis; 1991; 23(4):413-20. PubMed ID: 1957127 [TBL] [Abstract][Full Text] [Related]
2. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108 [TBL] [Abstract][Full Text] [Related]
3. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134 [TBL] [Abstract][Full Text] [Related]
4. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074 [TBL] [Abstract][Full Text] [Related]
5. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. Weiland O; Schvarcz R; Wejstål R; Norkrans G; Frydén A J Hepatol; 1990; 11 Suppl 1():S57-62. PubMed ID: 2127789 [TBL] [Abstract][Full Text] [Related]
6. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371 [TBL] [Abstract][Full Text] [Related]
7. Long-term histological outcome in patients with chronic hepatitis C treated repeatedly with interferon alpha-2b without sustained response. Reichard O; Glaumann H; Weiland O Scand J Infect Dis; 1994; 26(4):383-9. PubMed ID: 7984968 [TBL] [Abstract][Full Text] [Related]
8. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver. Reichen J; Bianchi L; Bühler H; Dolivo N; Gonvers JJ; Lavanchy D; Malé PJ; Renner EL; Solioz M; Schmid M; Zimmermann A J Hepatol; 1996 Sep; 25(3):275-82. PubMed ID: 8895005 [TBL] [Abstract][Full Text] [Related]
9. The clinical value of grading and staging scores for predicting a long-term response and evaluating the efficacy of interferon therapy in chronic hepatitis C. Shindo M; Arai K; Okuno T J Hepatol; 1997 Mar; 26(3):492-7. PubMed ID: 9075654 [TBL] [Abstract][Full Text] [Related]
10. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007 [TBL] [Abstract][Full Text] [Related]
11. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study. Weiland O; Schvarcz R; Wejstål R; Norkrans G; Foberg U; Frydén A Scand J Infect Dis; 1989; 21(2):127-32. PubMed ID: 2499037 [TBL] [Abstract][Full Text] [Related]